APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Drug CDMO Services

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oligonucleotide Drug CDMO Services Industry Growth and Trends Forecast to 2032

5 June 2026110 pages

Choose your research edition.

Industry ResearchOligonucleotide Drug CDMO Services Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Drug CDMO Services Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Drug CDMO Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Drug CDMO Services Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Drug CDMO Services Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

According to APO Research, the global Oligonucleotide Drug CDMO Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oligonucleotide Drug CDMO Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Oligonucleotide Drug CDMO Services market include Bachem, WuXi TIDES, Ajinomoto Co, Waters, AGC Biologics, Merck KGaA, EUROAPI, CordenPharma and Cytiva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oligonucleotide Drug CDMO Services market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oligonucleotide Drug CDMO Services market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oligonucleotide Drug CDMO Services market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oligonucleotide Drug CDMO Services.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Oligonucleotide Drug CDMO Services market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oligonucleotide Drug CDMO Services Market by Company

Bachem

WuXi TIDES

Ajinomoto Co

Waters

AGC Biologics

Merck KGaA

EUROAPI

CordenPharma

Cytiva

TriLink BioTechnologies

Medicilon

General Biol

BioSpring

Bio-Synthesis Inc

Aurisco

Suzhou Olipharma Co.,Ltd

Porton

RIBOPharm

Oligonucleotide Drug CDMO Services Segment by Type

API

Preparation

Oligonucleotide Drug CDMO Services Segment by Application

SME Pharmaceutical Company

Large Pharmaceutical Company

Oligonucleotide Drug CDMO Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Drug CDMO Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Drug CDMO Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Drug CDMO Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Oligonucleotide Drug CDMO Services companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Oligonucleotide Drug CDMO Services Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Oligonucleotide Drug CDMO Services Market Share by Region (2021-2026) Table 4. Global Oligonucleotide Drug CDMO Services Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Oligonucleotide Drug CDMO Services Market Share by Region (2027-2032) Table 6. Global Oligonucleotide Drug CDMO Services Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Oligonucleotide Drug CDMO Services Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Oligonucleotide Drug CDMO Services Market Size Share by Type (2021-2026) Table 9. Global Oligonucleotide Drug CDMO Services Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Oligonucleotide Drug CDMO Services Market Size Share Forecasted by Type (2027-2032) Table 11. North America Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Oligonucleotide Drug CDMO Services Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Oligonucleotide Drug CDMO Services Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Oligonucleotide Drug CDMO Services Market Size Share by Application (2021-2026) Table 24. Global Oligonucleotide Drug CDMO Services Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Oligonucleotide Drug CDMO Services Market Size Share Forecasted by Application (2027-2032) Table 26. North America Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Oligonucleotide Drug CDMO Services Industry Trends Table 37. Oligonucleotide Drug CDMO Services Industry Drivers Table 38. Oligonucleotide Drug CDMO Services Industry Opportunities and Challenges Table 39. Oligonucleotide Drug CDMO Services Industry Restraints Table 40. Global Oligonucleotide Drug CDMO Services Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Oligonucleotide Drug CDMO Services Revenue Market Share by Company (2021-2026) Table 42. Global Oligonucleotide Drug CDMO Services Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Oligonucleotide Drug CDMO Services Key Company Headquarters & Area Served Table 44. Global Oligonucleotide Drug CDMO Services Company, Product Type & Application Table 45. Global Oligonucleotide Drug CDMO Services Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Oligonucleotide Drug CDMO Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Bachem Company Information Table 49. Bachem Business Overview Table 50. Bachem Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Bachem Oligonucleotide Drug CDMO Services Product Portfolio Table 52. Bachem Recent Development Table 53. WuXi TIDES Company Information Table 54. WuXi TIDES Business Overview Table 55. WuXi TIDES Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. WuXi TIDES Oligonucleotide Drug CDMO Services Product Portfolio Table 57. WuXi TIDES Recent Development Table 58. Ajinomoto Co Company Information Table 59. Ajinomoto Co Business Overview Table 60. Ajinomoto Co Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Ajinomoto Co Oligonucleotide Drug CDMO Services Product Portfolio Table 62. Ajinomoto Co Recent Development Table 63. Waters Company Information Table 64. Waters Business Overview Table 65. Waters Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Waters Oligonucleotide Drug CDMO Services Product Portfolio Table 67. Waters Recent Development Table 68. AGC Biologics Company Information Table 69. AGC Biologics Business Overview Table 70. AGC Biologics Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. AGC Biologics Oligonucleotide Drug CDMO Services Product Portfolio Table 72. AGC Biologics Recent Development Table 73. Merck KGaA Company Information Table 74. Merck KGaA Business Overview Table 75. Merck KGaA Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Merck KGaA Oligonucleotide Drug CDMO Services Product Portfolio Table 77. Merck KGaA Recent Development Table 78. EUROAPI Company Information Table 79. EUROAPI Business Overview Table 80. EUROAPI Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. EUROAPI Oligonucleotide Drug CDMO Services Product Portfolio Table 82. EUROAPI Recent Development Table 83. CordenPharma Company Information Table 84. CordenPharma Business Overview Table 85. CordenPharma Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. CordenPharma Oligonucleotide Drug CDMO Services Product Portfolio Table 87. CordenPharma Recent Development Table 88. Cytiva Company Information Table 89. Cytiva Business Overview Table 90. Cytiva Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Cytiva Oligonucleotide Drug CDMO Services Product Portfolio Table 92. Cytiva Recent Development Table 93. TriLink BioTechnologies Company Information Table 94. TriLink BioTechnologies Business Overview Table 95. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product Portfolio Table 97. TriLink BioTechnologies Recent Development Table 98. Medicilon Company Information Table 99. Medicilon Business Overview Table 100. Medicilon Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Medicilon Oligonucleotide Drug CDMO Services Product Portfolio Table 102. Medicilon Recent Development Table 103. General Biol Company Information Table 104. General Biol Business Overview Table 105. General Biol Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. General Biol Oligonucleotide Drug CDMO Services Product Portfolio Table 107. General Biol Recent Development Table 108. BioSpring Company Information Table 109. BioSpring Business Overview Table 110. BioSpring Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. BioSpring Oligonucleotide Drug CDMO Services Product Portfolio Table 112. BioSpring Recent Development Table 113. Bio-Synthesis Inc Company Information Table 114. Bio-Synthesis Inc Business Overview Table 115. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product Portfolio Table 117. Bio-Synthesis Inc Recent Development Table 118. Aurisco Company Information Table 119. Aurisco Business Overview Table 120. Aurisco Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Aurisco Oligonucleotide Drug CDMO Services Product Portfolio Table 122. Aurisco Recent Development Table 123. Suzhou Olipharma Co.,Ltd Company Information Table 124. Suzhou Olipharma Co.,Ltd Business Overview Table 125. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product Portfolio Table 127. Suzhou Olipharma Co.,Ltd Recent Development Table 128. Porton Company Information Table 129. Porton Business Overview Table 130. Porton Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. Porton Oligonucleotide Drug CDMO Services Product Portfolio Table 132. Porton Recent Development Table 133. RIBOPharm Company Information Table 134. RIBOPharm Business Overview Table 135. RIBOPharm Oligonucleotide Drug CDMO Services Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. RIBOPharm Oligonucleotide Drug CDMO Services Product Portfolio Table 137. RIBOPharm Recent Development Table 138. North America Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 139. North America Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026) & (US$ Million) Table 140. North America Oligonucleotide Drug CDMO Services Market Share by Country (2021-2026) Table 141. North America Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032) & (US$ Million) Table 142. North America Oligonucleotide Drug CDMO Services Market Share Forecast by Country (2027-2032) Table 143. Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 144. Europe Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026) & (US$ Million) Table 145. Europe Oligonucleotide Drug CDMO Services Market Share by Country (2021-2026) Table 146. Europe Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032) & (US$ Million) Table 147. Europe Oligonucleotide Drug CDMO Services Market Share Forecast by Country (2027-2032) Table 148. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026) & (US$ Million) Table 150. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Country (2021-2026) Table 151. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share Forecast by Country (2027-2032) Table 153. Latin America Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Latin America Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026) & (US$ Million) Table 155. Latin America Oligonucleotide Drug CDMO Services Market Share by Country (2021-2026) Table 156. Latin America Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Latin America Oligonucleotide Drug CDMO Services Market Share Forecast by Country (2027-2032) Table 158. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026) & (US$ Million) Table 160. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Country (2021-2026) Table 161. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share Forecast by Country (2027-2032) Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Oligonucleotide Drug CDMO Services Product Image Figure 3. Global Oligonucleotide Drug CDMO Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Oligonucleotide Drug CDMO Services Market Size (2021-2032) & (US$ Million) Figure 5. Global Oligonucleotide Drug CDMO Services Market Share by Region: 2025 VS 2032 Figure 6. Global Oligonucleotide Drug CDMO Services Market Share by Region (2021-2032) Figure 7. North America Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. API Image Figure 13. Global API Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Preparation Image Figure 15. Global Preparation Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Global Oligonucleotide Drug CDMO Services Market Size Overview by Type (2021-2032) & (US$ Million) Figure 17. Global Oligonucleotide Drug CDMO Services Market Share by Type 2025 VS 2032 Figure 18. North America Oligonucleotide Drug CDMO Services Market Size Share by Type (2021-2032) Figure 19. Europe Oligonucleotide Drug CDMO Services Market Size Share by Type (2021-2032) Figure 20. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Share by Type (2021-2032) Figure 21. Latin America Oligonucleotide Drug CDMO Services Market Size Share by Type (2021-2032) Figure 22. Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Share by Type (2021-2032) Figure 23. SME Pharmaceutical Company Image Figure 24. Global SME Pharmaceutical Company Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Large Pharmaceutical Company Image Figure 26. Global Large Pharmaceutical Company Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Global Oligonucleotide Drug CDMO Services Market Size Overview by Application (2021-2032) & (US$ Million) Figure 28. Global Oligonucleotide Drug CDMO Services Market Share by Application 2025 VS 2032 Figure 29. North America Oligonucleotide Drug CDMO Services Market Size Share by Application (2021-2032) Figure 30. Europe Oligonucleotide Drug CDMO Services Market Size Share by Application (2021-2032) Figure 31. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Share by Application (2021-2032) Figure 32. Latin America Oligonucleotide Drug CDMO Services Market Size Share by Application (2021-2032) Figure 33. Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Share by Application (2021-2032) Figure 34. Global Top 5 and 10 Oligonucleotide Drug CDMO Services Players Market Share by Revenue in 2025 Figure 35. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 36. North America Oligonucleotide Drug CDMO Services Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. North America Oligonucleotide Drug CDMO Services Market Share by Country: 2021 VS 2025 VS 2032 Figure 38. North America Oligonucleotide Drug CDMO Services Market Share by Country (2021-2032) Figure 39. Europe Oligonucleotide Drug CDMO Services Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 40. Europe Oligonucleotide Drug CDMO Services Market Share by Country: 2021 VS 2025 VS 2032 Figure 41. Europe Oligonucleotide Drug CDMO Services Market Share by Country (2021-2032) Figure 42. Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. Asia-Pacific Oligonucleotide Drug CDMO Services Market Share by Country (2021-2032) Figure 45. Latin America Oligonucleotide Drug CDMO Services Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Latin America Oligonucleotide Drug CDMO Services Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Latin America Oligonucleotide Drug CDMO Services Market Share by Country (2021-2032) Figure 48. Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Middle East & Africa Oligonucleotide Drug CDMO Services Market Share by Country (2021-2032) Figure 51. Years Considered Figure 52. Research Process Figure 53. Key Executives Interviewed

Scope & coverage.

Types
  • API
  • Preparation
Applications
  • SME Pharmaceutical Company
  • Large Pharmaceutical Company
Companies covered
  • Bachem
  • WuXi TIDES
  • Ajinomoto Co
  • Waters
  • AGC Biologics
  • Merck KGaA
  • EUROAPI
  • CordenPharma
  • Cytiva
  • TriLink BioTechnologies
  • Medicilon
  • General Biol
  • BioSpring
  • Bio-Synthesis Inc
  • Aurisco
  • Suzhou Olipharma Co.,Ltd
  • Porton
  • RIBOPharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Oligonucleotide Drug CDMO Services Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Oligonucleotide Drug CDMO Services Market Size by Region (2021-2032)
  5. 1.4.1 Global Oligonucleotide Drug CDMO Services Market Size by Region (2021-2026)
  6. 1.4.2 Global Oligonucleotide Drug CDMO Services Market Size by Region (2027-2032)
  7. 1.5 Key Regions Oligonucleotide Drug CDMO Services Market Size (2021-2032)
  8. 1.5.1 North America Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate (2021-2032)
2 Oligonucleotide Drug CDMO Services Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 API
  3. 2.1.2 Preparation
  4. 2.2 Global Oligonucleotide Drug CDMO Services Market Size by Type
  5. 2.2.1 Global Oligonucleotide Drug CDMO Services Market Size Overview by Type (2021-2032)
  6. 2.2.2 Global Oligonucleotide Drug CDMO Services Historic Market Size Review by Type (2021-2026)
  7. 2.2.3 Global Oligonucleotide Drug CDMO Services Market Size Forecasted by Type (2027-2032)
  8. 2.3 Global Oligonucleotide Drug CDMO Services Market Size by Regions
  9. 2.3.1 North America Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026)
  10. 2.3.2 Europe Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026)
  11. 2.3.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026)
  12. 2.3.4 South America Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026)
  13. 2.3.5 Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Breakdown by Type (2021-2026)
3 Oligonucleotide Drug CDMO Services Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 SME Pharmaceutical Company
  3. 3.1.2 Large Pharmaceutical Company
  4. 3.2 Global Oligonucleotide Drug CDMO Services Market Size by Application
  5. 3.2.1 Global Oligonucleotide Drug CDMO Services Market Size Overview by Application (2021-2032)
  6. 3.2.2 Global Oligonucleotide Drug CDMO Services Historic Market Size Review by Application (2021-2026)
  7. 3.2.3 Global Oligonucleotide Drug CDMO Services Market Size Forecasted by Application (2027-2032)
  8. 3.3 Global Oligonucleotide Drug CDMO Services Market Size by Regions
  9. 3.3.1 North America Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026)
  10. 3.3.2 Europe Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026)
  11. 3.3.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026)
  12. 3.3.4 South America Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026)
  13. 3.3.5 Middle East and Africa Oligonucleotide Drug CDMO Services Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Oligonucleotide Drug CDMO Services Industry Trends
  2. 4.2 Oligonucleotide Drug CDMO Services Industry Drivers
  3. 4.3 Oligonucleotide Drug CDMO Services Industry Opportunities and Challenges
  4. 4.4 Oligonucleotide Drug CDMO Services Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Oligonucleotide Drug CDMO Services Revenue (2021-2026)
  2. 5.2 Global Oligonucleotide Drug CDMO Services Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Oligonucleotide Drug CDMO Services Key Company Headquarters & Area Served
  4. 5.4 Global Oligonucleotide Drug CDMO Services Company, Product Type & Application
  5. 5.5 Global Oligonucleotide Drug CDMO Services Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Oligonucleotide Drug CDMO Services Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Oligonucleotide Drug CDMO Services Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Oligonucleotide Drug CDMO Services Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Bachem
  2. 6.1.1 Bachem Company Information
  3. 6.1.2 Bachem Business Overview
  4. 6.1.3 Bachem Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Bachem Oligonucleotide Drug CDMO Services Product Portfolio
  6. 6.1.5 Bachem Recent Developments
  7. 6.2 WuXi TIDES
  8. 6.2.1 WuXi TIDES Company Information
  9. 6.2.2 WuXi TIDES Business Overview
  10. 6.2.3 WuXi TIDES Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 WuXi TIDES Oligonucleotide Drug CDMO Services Product Portfolio
  12. 6.2.5 WuXi TIDES Recent Developments
  13. 6.3 Ajinomoto Co
  14. 6.3.1 Ajinomoto Co Company Information
  15. 6.3.2 Ajinomoto Co Business Overview
  16. 6.3.3 Ajinomoto Co Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Ajinomoto Co Oligonucleotide Drug CDMO Services Product Portfolio
  18. 6.3.5 Ajinomoto Co Recent Developments
  19. 6.4 Waters
  20. 6.4.1 Waters Company Information
  21. 6.4.2 Waters Business Overview
  22. 6.4.3 Waters Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Waters Oligonucleotide Drug CDMO Services Product Portfolio
  24. 6.4.5 Waters Recent Developments
  25. 6.5 AGC Biologics
  26. 6.5.1 AGC Biologics Company Information
  27. 6.5.2 AGC Biologics Business Overview
  28. 6.5.3 AGC Biologics Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 AGC Biologics Oligonucleotide Drug CDMO Services Product Portfolio
  30. 6.5.5 AGC Biologics Recent Developments
  31. 6.6 Merck KGaA
  32. 6.6.1 Merck KGaA Company Information
  33. 6.6.2 Merck KGaA Business Overview
  34. 6.6.3 Merck KGaA Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Merck KGaA Oligonucleotide Drug CDMO Services Product Portfolio
  36. 6.6.5 Merck KGaA Recent Developments
  37. 6.7 EUROAPI
  38. 6.7.1 EUROAPI Company Information
  39. 6.7.2 EUROAPI Business Overview
  40. 6.7.3 EUROAPI Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 EUROAPI Oligonucleotide Drug CDMO Services Product Portfolio
  42. 6.7.5 EUROAPI Recent Developments
  43. 6.8 CordenPharma
  44. 6.8.1 CordenPharma Company Information
  45. 6.8.2 CordenPharma Business Overview
  46. 6.8.3 CordenPharma Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 CordenPharma Oligonucleotide Drug CDMO Services Product Portfolio
  48. 6.8.5 CordenPharma Recent Developments
  49. 6.9 Cytiva
  50. 6.9.1 Cytiva Company Information
  51. 6.9.2 Cytiva Business Overview
  52. 6.9.3 Cytiva Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Cytiva Oligonucleotide Drug CDMO Services Product Portfolio
  54. 6.9.5 Cytiva Recent Developments
  55. 6.10 TriLink BioTechnologies
  56. 6.10.1 TriLink BioTechnologies Company Information
  57. 6.10.2 TriLink BioTechnologies Business Overview
  58. 6.10.3 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 TriLink BioTechnologies Oligonucleotide Drug CDMO Services Product Portfolio
  60. 6.10.5 TriLink BioTechnologies Recent Developments
  61. 6.11 Medicilon
  62. 6.11.1 Medicilon Company Information
  63. 6.11.2 Medicilon Business Overview
  64. 6.11.3 Medicilon Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Medicilon Oligonucleotide Drug CDMO Services Product Portfolio
  66. 6.11.5 Medicilon Recent Developments
  67. 6.12 General Biol
  68. 6.12.1 General Biol Company Information
  69. 6.12.2 General Biol Business Overview
  70. 6.12.3 General Biol Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 General Biol Oligonucleotide Drug CDMO Services Product Portfolio
  72. 6.12.5 General Biol Recent Developments
  73. 6.13 BioSpring
  74. 6.13.1 BioSpring Company Information
  75. 6.13.2 BioSpring Business Overview
  76. 6.13.3 BioSpring Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 BioSpring Oligonucleotide Drug CDMO Services Product Portfolio
  78. 6.13.5 BioSpring Recent Developments
  79. 6.14 Bio-Synthesis Inc
  80. 6.14.1 Bio-Synthesis Inc Company Information
  81. 6.14.2 Bio-Synthesis Inc Business Overview
  82. 6.14.3 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Bio-Synthesis Inc Oligonucleotide Drug CDMO Services Product Portfolio
  84. 6.14.5 Bio-Synthesis Inc Recent Developments
  85. 6.15 Aurisco
  86. 6.15.1 Aurisco Company Information
  87. 6.15.2 Aurisco Business Overview
  88. 6.15.3 Aurisco Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Aurisco Oligonucleotide Drug CDMO Services Product Portfolio
  90. 6.15.5 Aurisco Recent Developments
  91. 6.16 Suzhou Olipharma Co.,Ltd
  92. 6.16.1 Suzhou Olipharma Co.,Ltd Company Information
  93. 6.16.2 Suzhou Olipharma Co.,Ltd Business Overview
  94. 6.16.3 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Suzhou Olipharma Co.,Ltd Oligonucleotide Drug CDMO Services Product Portfolio
  96. 6.16.5 Suzhou Olipharma Co.,Ltd Recent Developments
  97. 6.17 Porton
  98. 6.17.1 Porton Company Information
  99. 6.17.2 Porton Business Overview
  100. 6.17.3 Porton Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 Porton Oligonucleotide Drug CDMO Services Product Portfolio
  102. 6.17.5 Porton Recent Developments
  103. 6.18 RIBOPharm
  104. 6.18.1 RIBOPharm Company Information
  105. 6.18.2 RIBOPharm Business Overview
  106. 6.18.3 RIBOPharm Oligonucleotide Drug CDMO Services Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 RIBOPharm Oligonucleotide Drug CDMO Services Product Portfolio
  108. 6.18.5 RIBOPharm Recent Developments
7 North America
  1. 7.1 North America Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
  3. 7.3 North America Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
  3. 8.3 Europe Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
  3. 10.3 South America Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Oligonucleotide Drug CDMO Services Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst